Anxiety in children of male alcoholics under treatment

Nuestro trabajo pretende valorar la importancia que determinadas variables descriptoras de la enfermedad y del estrés familiar juegan en el niño, una vez que el enfermo alcohólico se integra en un programa de tratamiento. Seleccionamos una muestra de 155 niños entre 9 y 18 años, con una edad media de 13.44; todos eran hijos de padres alcohólicos en tratamiento y procedían de 93 familias. Los instrumentos utilizados, además de una entrevista semiestructurada, consistieron en una batería de test psicológicos: FES, STAI, STAIC, CMAS y CAST. Una vez analizados los resultados concluimos que la estabilidad emocional del hijo de enfermo alcohólico en tratamiento viene caracterizada por: niveles bajos de ansiedad en ambos padres, principalmente en el padre, y una vivencia positiva de la enfermedad del padre. Además, la ansiedad del hijo de alcohólico en tratamiento viene influida de forma indirecta por la estabilidad familiar y unas adecuadas relaciones internas entre los miembros. Los resultados obtenidos nos hacen ser optimistas debido a que el tratamiento recibido parece ejercer una notable influencia positiva, no sólo para el enfermo alcohólico sino también para el resto de la familia y especialmente para los hijos.Our investigation proposes to value the importance that family stress and certain variables descriptive of the parental disease play in the child, once the alcoholic patient has been set in a treatment program. We selected a sample of 155 children between 9 and 18 years old. The procedures used included, in addition to a semi-structured interview, a battery of psychological test: FES, STAI, STAIC, CMAS and CAST. Once the results were analyzed, our conclusion was that the emotional stability of the child of male alcoholics under treatment is characterized by low levels of anxiety in both parents, primarily in the father, and by a positive attitude towards the father’s disease. At the same time, such relationships are, in one way or another, tinged with family stability and adequate internal relationships among its members. Finally, our results make us optimistic due to the fact that the treatment received by these alcoholic patients seems not only to have positively influenced them, but also the rest of their families and, especially, their children

Epilepsy in adults and elderly in a Mexican population

Objetivo: Reportar la etiología y la experiencia del manejo de la epilepsia en adultos y ancianos en una población mexicana. Material y método: Realizamos un estudio transversal en adultos y ancianos con epilepsia. Los pacientes fueron dicotomizados en menores y mayores de 65 anos ˜ de edad. Resultados: De los 149 pacientes incluidos, 131 eran menores de 65 anos ˜ (38,1 ± 13,2) y 18 mayores de 65 anos ˜ (72,8 ± 6,9). Predominó un patrón de crisis generalizadas motoras en el grupo menor de 65 anos ˜ y un patrón de crisis focales motoras en el grupo mayor de 65 anos ˜ (p < 0,001). La primera causa de epilepsia en los pacientes menores de 65 anos ˜ fue el trauma craneal (42,7%), mientras que en los mayores de 65 anos ˜ lo fue el infarto cerebral (72,2%). La neurocisticercosis fue la causa de epilepsia en un 36,6% de los pacientes menores de 65 anos ˜ y en un 38,9% de los mayores de 65 anos ˜ (p = 0,52). El tumor cerebral como causa de epilepsia en edad adulta representó únicamente el 3,1% de los casos del grupo menor de 65 anos ˜ y el 5,6% del grupo mayor de 65 anos. ˜ Comentario: Nuestro estudio muestra que las principales causas de epilepsia de inicio en la edad adulta y en los ancianos, son en su mayoría prevenibles, por lo que es importante realizar programas de prevención primaria o secundaria para evitar su desarrollo.Objective: To report the etiology and management experience in epilepsy in adults and elderly people in the Mexican population. Material and method: We carried out a cross-sectional study in epilepsy in adults and elderly. The patients were dichotomized into those under and over 65 years of age. Results: Of the 149 patients included, 131 were under 65 years of age (38.1±13.2), and 18 were over 65 years of age (72.8±6.9). General onset motor seizures were more frequent in the group under 65 years of age while focal onset motor seizures were more prevalent in the group over 65 years of age (P<.001). The first cause of epilepsy in patients under 65 years of age was head trauma (42.7%), while in those over 65 years it was cerebral infarction (72.2%). Neurocysticercosis was the cause of epilepsy in 36.6% of patients under 65 years of age and in 38.9% of those over 65 years of age (P=.52). Brain tumor as a cause of epilepsy in adulthood represented only 3.1% of cases in the group under 65 years of age and 5.6% in the group over 65 years of age. Comment: Our study shows that the main causes of epilepsy in adults and elderly are mostly preventable, so it is important to carry out primary or secondary prevention programs to prevent their development

A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial

BACKGROUND: Fragile X syndrome (FXS) is an inherited neurodevelopmental condition characterised by behavioural, learning disabilities, phisical and neurological symptoms. In addition, an important degree of comorbidity with autism is also present. Considered a rare disorder affecting both genders, it first becomes apparent during childhood with displays of language delay and behavioural symptoms. Main aim: To show whether the combination of 10 mg/kg/day of ascorbic acid (vitamin C) and 10 mg/kg/day of α-tocopherol (vitamin E) reduces FXS symptoms among male patients ages 6 to 18 years compared to placebo treatment, as measured on the standardized rating scales at baseline, and after 12 and 24 weeks of treatment. Secondary aims: To assess the safety of the treatment. To describe behavioural and cognitive changes revealed by the Developmental Behaviour Checklist Short Form (DBC-P24) and the Wechsler Intelligence Scale for Children–Revised. To describe metabolic changes revealed by blood analysis. To measure treatment impact at home and in an academic environment. METHODS/DESIGN: A phase II randomized, double-blind pilot clinical trial. Scope: male children and adolescents diagnosed with FXS, in accordance with a standardized molecular biology test, who met all the inclusion criteria and none of the exclusion criteria. Instrumentation: clinical data, blood analysis, Wechsler Intelligence Scale for Children–Revised, Conners parent and teacher rating scale scores and the DBC-P24 results will be obtained at the baseline (t0). Follow up examinations will take place at 12 weeks (t1) and 24 weeks (t2) of treatment. DISCUSSION: A limited number of clinical trials have been carried out on children with FXS, but more are necessary as current treatment possibilities are insufficient and often provoke side effects. In the present study, we sought to overcome possible methodological problems by conducting a phase II pilot study in order to calculate the relevant statistical parameters and determine the safety of the proposed treatment. The results will provide evidence to improve hyperactivity control and reduce behavioural and learning problems using ascorbic acid (vitamin C) and α-tocopherol (vitamin E). The study protocol was approved by the Regional Government Committee for Clinical Trials in Andalusia and the Spanish agency for drugs and health products. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01329770 (29 March 2011

Internationalisation of Higher Education in South East Asia: a Perspective from the Marco Polo Project

As the leading partner in the Marco Polo Project, the University of Seville is proud to publish this work. The publication contains essential contributions to the ongoing Higher Education internationalisation debate, but from a new and challenging perspective that of South East Asia. Como socio líder en el Proyecto Marco Polo, la Universidad de Sevilla se enorgullece en publicar este trabajo. La publicación contiene contribuciones esenciales para el curso superior Debate de internacionalización educativa, pero desde un nuevo y desafiante perspectiva: la del sudeste asiático

A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0).[Background]: Fragile X syndrome (FXS) is an inherited neurodevelopmental condition characterised by behavioural, learning disabilities, phisical and neurological symptoms. In addition, an important degree of comorbidity with autism is also present. Considered a rare disorder affecting both genders, it first becomes apparent during childhood with displays of language delay and behavioural symptoms.Main aim: To show whether the combination of 10 mg/kg/day of ascorbic acid (vitamin C) and 10 mg/kg/day of α-tocopherol (vitamin E) reduces FXS symptoms among male patients ages 6 to 18 years compared to placebo treatment, as measured on the standardized rating scales at baseline, and after 12 and 24 weeks of treatment. Secondary aims: To assess the safety of the treatment. To describe behavioural and cognitive changes revealed by the Developmental Behaviour Checklist Short Form (DBC-P24) and the Wechsler Intelligence Scale for Children-Revised. To describe metabolic changes revealed by blood analysis. To measure treatment impact at home and in an academic environment. [Methods/Design]: A phase II randomized, double-blind pilot clinical trial. Scope: male children and adolescents diagnosed with FXS, in accordance with a standardized molecular biology test, who met all the inclusion criteria and none of the exclusion criteria. Instrumentation: clinical data, blood analysis, Wechsler Intelligence Scale for Children-Revised, Conners parent and teacher rating scale scores and the DBC-P24 results will be obtained at the baseline (t0). Follow up examinations will take place at 12 weeks (t1) and 24 weeks (t2) of treatment. [Discussion]: A limited number of clinical trials have been carried out on children with FXS, but more are necessary as current treatment possibilities are insufficient and often provoke side effects. In the present study, we sought to overcome possible methodological problems by conducting a phase II pilot study in order to calculate the relevant statistical parameters and determine the safety of the proposed treatment. The results will provide evidence to improve hyperactivity control and reduce behavioural and learning problems using ascorbic acid (vitamin C) and α-tocopherol (vitamin E). The study protocol was approved by the Regional Government Committee for Clinical Trials in Andalusia and the Spanish agency for drugs and health products. [Trial registration]: ClinicalTrials.gov Identifier: NCT01329770 (29 March 2011).The trial protocol is approved and funded by the Spanish Ministry of Health, Research Funds from FEDER-EU (TRA152, EC10-191 and EC11-434), the Health Department of the Andalusian Regional Government (PI09-0507), the Economic Innovation and Science Regional Government (CTS546 and P10-CTS-05704) and the Jerome Lejeune Foundation (Paris, France). YDDO is the recipient of a Nicolas Monarde contract from the Servicio Andaluz de Salud. Consejería de Salud. Junta de Andalucía.Peer Reviewe

A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial.

Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;BACKGROUND Fragile X syndrome (FXS) is an inherited neurodevelopmental condition characterised by behavioural, learning disabilities, physical and neurological symptoms. In addition, an important degree of comorbidity with autism is also present. Considered a rare disorder affecting both genders, it first becomes apparent during childhood with displays of language delay and behavioural symptoms.Main aim: To show whether the combination of 10 mg/kg/day of ascorbic acid (vitamin C) and 10 mg/kg/day of α-tocopherol (vitamin E) reduces FXS symptoms among male patients ages 6 to 18 years compared to placebo treatment, as measured on the standardized rating scales at baseline, and after 12 and 24 weeks of treatment.Secondary aims: To assess the safety of the treatment. To describe behavioural and cognitive changes revealed by the Developmental Behaviour Checklist Short Form (DBC-P24) and the Wechsler Intelligence Scale for Children-Revised. To describe metabolic changes revealed by blood analysis. To measure treatment impact at home and in an academic environment. METHODS/DESIGN A phase II randomized, double-blind pilot clinical trial. SCOPE male children and adolescents diagnosed with FXS, in accordance with a standardized molecular biology test, who met all the inclusion criteria and none of the exclusion criteria. INSTRUMENTATION clinical data, blood analysis, Wechsler Intelligence Scale for Children-Revised, Conners parent and teacher rating scale scores and the DBC-P24 results will be obtained at the baseline (t0). Follow up examinations will take place at 12 weeks (t1) and 24 weeks (t2) of treatment. DISCUSSION A limited number of clinical trials have been carried out on children with FXS, but more are necessary as current treatment possibilities are insufficient and often provoke side effects. In the present study, we sought to overcome possible methodological problems by conducting a phase II pilot study in order to calculate the relevant statistical parameters and determine the safety of the proposed treatment. The results will provide evidence to improve hyperactivity control and reduce behavioural and learning problems using ascorbic acid (vitamin C) and α-tocopherol (vitamin E). The study protocol was approved by the Regional Government Committee for Clinical Trials in Andalusia and the Spanish agency for drugs and health products. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01329770 (29 March 2011).the Spanish Ministry of Health, Research Funds from FEDER-EU (TRA152, EC10-191 and EC11-434), the Health Department of the Andalusian Regional Government (PI09-0507), the Economic Innovation and Science Regional Government (CTS546 and P10-CTS-05704) and the Jerome Lejeune Foundation (Paris, France).Ye

Tabla de equivalencias entre la Organización Diagnóstica de Atención Temprana (ODAT) y la Clasificación Internacional de Enfermedades (CIE)

Publicado en la página web de la Consejería de Salud y Bienestar Social: www.juntadeandalucia.es/salud (Consejería de Salud y Bienestar Social/ Profesionales / Salud Pública /Prevención / Atención Temprana /)YesLa Consejería de Salud de la Junta de Andalucía ha lanzado el Sistema de Información de Atención Temprana (alborada) que tiene la finalidad de ser una herramienta que favorezca la coordinación y continuidad de la Atención Temprana, poniendo en contacto a todos los actores relacionados con la intervención sobre menores con trastornos del desarrollo o riesgo de padecerlos y sus familias. Para poder conseguir los objetivos planteados en esta Sistema de Información ha sido necesario crear una tabla de equivalencias o una tabla de equivalencias entre la codificación diagnóstica utilizada en la Historia de Salud Digital del Servicio Andaluz de Salud (CIE 9 - CIE 10) y los diagnósticos ODAT, (Organización Diagnóstica de Atención Temprana)

Llamando a la puerta azul. Al lado del menor en situación de adversidad en salud

Contiene: Llamando a la puertazul. Al lado del menor en situación de adversidad en salud (173 p.); Anexo 1. Así se realizó (45 p.); Anexo 2. Relación de biográficos (32 p.); Anexo 3. Instrumentos para la recuperación (19 p.); Anexo 4. Recomendaciones operativas en cuidados paliativos a menores (14 p.); Recopilar y resaltar (32 p.). Publicado en la página de la Consejería de Salud: www.juntadeandalucia.es/salud (Consejería de Salud / Ciudadanía / Participar. Subvenciones / 'Al Lado' con... / 'Al Lado' del Menor en situación de alta adversidad en salud)I. Un proyecto para estar al lado de menores en situación de adversidad en salud. II. Partiendo de las necesidades. III. Estrategias transversales. IV. Itinerario de atención compartida, como instrumento de seguimiento y mejora. V. Teniendo en cuenta el grado de adversidad. VI. Alta adversidad y cuidados paliativos en el menor. 1. Sobre el concepto, las oportunidades y los escenarios de los cuidados paliativos en las personas menores. 2. Necesidades del menor en situación terminal y su familia. 3. Los últimos días. 4. La atención al dueloYes'Al lado del menor en situación de adversidad en Salud' pretende, desde un modelo basado en la cooperación, estar “al lado” en el proceso de recuperación de menores afectados por una enfermedad y de sus familias, en colaboración entre los servicios de salud y las asociaciones